<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="phs" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">phs</book-part-id>
      <title-group>
        <title>Pallister-Hall Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Biesecker</surname>
            <given-names>Leslie G</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Medical Genomics and Metabolic Genetics Branch <break/>National Human Genome Research Institute <break/>National Institutes of Health <break/>Bethesda, Maryland</aff>
          <email>lesb@mail.nih.gov</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>25</day>
          <month>5</month>
          <year>2000</year>
        </date>
        <date date-type="updated">
          <day>18</day>
          <month>5</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>15</day>
          <month>6</month>
          <year>2010</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="pc" document-type="chapter">Pachyonychia Congenita</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="pancreatitis-ov" document-type="chapter">Pancreatitis Overview</related-object>
      <abstract id="phs.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Pallister-Hall syndrome (referred to as PHS in this entry) is characterized by a spectrum of anomalies ranging from polydactyly, asymptomatic bifid epiglottis, and hypothalamic hamartoma at the mild end to laryngotracheal cleft with neonatal lethality at the severe end. Individuals with mild PHS may be incorrectly diagnosed as having isolated postaxial polydactyly type A. Individuals with PHS can have pituitary insufficiency and may die as neonates from undiagnosed and untreated adrenal insufficiency.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of Pallister-Hall syndrome can be established in a proband with both hypothalamic hamartoma and mesoaxial polydactyly. Identification of a heterozygous pathogenic variant in <italic toggle="yes">GLI3</italic> confirms the diagnosis.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Urgent treatment for endocrine abnormalities, especially cortisol deficiency; management of epiglottic abnormalities depending on the abnormality and the extent of respiratory compromise. Bifid epiglottis, the most common abnormality, typically does not need treatment. Standard treatment of anal atresia or stenosis; symptomatic treatment of seizures; elective repair of polydactyly; developmental intervention or special education for developmental delays.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Biopsy or resection of hypothalamic hamartoma may result in complications and lifelong need for hormone replacement; seizures may begin or worsen with use of stimulants for attention deficit disorder.</p>
          <p><italic toggle="yes">Surveillance:</italic> During childhood, annual developmental assessment and annual medical evaluation to assess growth and monitor for signs of precocious puberty.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Pallister-Hall syndrome is inherited in an autosomal dominant manner. Individuals with PHS may have an affected parent or may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. About 25% of individuals have a <italic toggle="yes">de novo</italic> pathogenic variant. Persons with <italic toggle="yes">de novo</italic> pathogenic variant are generally more severely affected than those with a family history of PHS. The risk to offspring of an affected individual is 50%. Prenatal testing for pregnancies at increased risk is possible if the pathogenic variant in the family is known. The reliability of ultrasound examination for prenatal diagnosis is unknown.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="phs.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="phs.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_phs.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_phs.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Pallister-Hall syndrome (PHS)</p></list-item><list-item><p>Sub-Pallister-Hall syndrome (Sub-PHS)</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="phs.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="phs.Diagnosis">
        <title>Diagnosis</title>
        <sec id="phs.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Pallister-Hall syndrome (PHS) <bold>should be suspected</bold> in individuals with the following features:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Hypothalamic hamartoma,</bold> a non-enhancing mass in the floor of the third ventricle posterior to the optic chiasm that is isointense to gray matter on T<sub>1</sub> and T<sub>2</sub> pulse sequences of an MRI, but may have distinct intensity on FLAIR</p>
              <p>Note: Neither cranial CT examination nor cranial ultrasound examination is adequate for diagnosis of hypothalamic hamartoma.</p>
            </list-item>
            <list-item>
              <p><bold>Mesoaxial (i.e., insertional or central) polydactyly,</bold> the presence of six or more well-formed digits with a 'Y'-shaped metacarpal or metatarsal</p>
            </list-item>
            <list-item>
              <p><bold>Postaxial polydactyly (PAP) types A and B.</bold> PAP-A is the presence of a well-formed digit on the ulnar or fibular aspect of the limb. PAP-B is the presence of a rudimentary digit or nubbin in the same location. Postaxial polydactyly is probably more common than mesoaxial polydactyly; however, the nonspecificity of postaxial polydactyly and the high frequency of postaxial polydactyly type B in persons of central African descent require caution in its use as a diagnostic feature.</p>
            </list-item>
            <list-item>
              <p><bold>Bifid epiglottis,</bold> a midline anterior-posterior cleft of the epiglottis that involves at least two thirds of the epiglottic leaf. It is a useful feature for clinical diagnosis because it appears to be very rare in syndromes other than PHS and is also rare as an isolated malformation.</p>
            </list-item>
            <list-item>
              <p><bold>Other.</bold> Imperforate anus, renal abnormalities including cystic malformations, renal hypoplasia, ectopic ureteral implantation, genitourinary anomalies including hydrometrocolpos, pulmonary segmentation anomalies including bilateral bilobed lungs, and non-polydactyly skeletal anomalies including short limbs</p>
            </list-item>
          </list>
        </sec>
        <sec id="phs.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The clinical diagnosis of <bold>PHS is established</bold> in a proband with BOTH hypothalamic hamartoma and mesoaxial polydactyly.</p>
          <p>Identification of a heterozygous pathogenic variant in <italic toggle="yes">GLI3</italic> by molecular genetic testing confirms the diagnosis of PHS (see <xref ref-type="table" rid="phs.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>The clinical diagnosis of <bold>sub-PHS is established</bold> in a proband with:</p>
          <list list-type="bullet">
            <list-item>
              <p>One of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Mesoaxial polydactyly</p>
                </list-item>
                <list-item>
                  <p>Hypothalamic hamartoma</p>
                </list-item>
                <list-item>
                  <p>Oligodactyly</p>
                </list-item>
                <list-item>
                  <p>Postaxial polydactyly; AND</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>One of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Bifid epiglottis</p>
                </list-item>
                <list-item>
                  <p>Imperforate anus</p>
                </list-item>
                <list-item>
                  <p>Small nails</p>
                </list-item>
                <list-item>
                  <p>Hypopituitarism</p>
                </list-item>
                <list-item>
                  <p>Growth hormone deficiency</p>
                </list-item>
                <list-item>
                  <p>Genital hypoplasia</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Identification of a heterozygous pathogenic variant in <italic toggle="yes">GLI3</italic> by molecular genetic testing confirms the diagnosis of sub-PHS (see <xref ref-type="table" rid="phs.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>Note: Several individuals with nonsyndromic hypothalamic hamartomas and somatic mosaicism for <italic toggle="yes">GLI3</italic> pathogenic variants in the hamartoma have been reported [<xref ref-type="bibr" rid="phs.REF.wallace.2008.653">Wallace et al 2008</xref>]. While these individuals do not meet the clinical diagnostic criteria for PHS <italic toggle="yes">sensu stricto</italic>, they may be considered to have a partial form of PHS and consideration should be given to evaluating such individuals for other manifestations of the disorder.</p>
          <sec id="phs.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive genomic testing</bold>:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">GLI3</italic> is performed first and followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found.</p>
              </list-item>
              <list-item>
                <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">GLI3</italic> and other genes of interest (see <xref ref-type="sec" rid="phs.Differential_Diagnosis">Differential Diagnosis</xref>) may be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene varies by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
                <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
              </list-item>
              <list-item>
                <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
              </list-item>
            </list>
            <table-wrap id="phs.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in Pallister-Hall Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">GLI3</italic>
                    </td>
                    <td headers="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">20/22&#x000a0;<sup>4,5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                    <td headers="hd_h_phs.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="phs.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="phs" object-id="phs.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="phs.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="phs.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="phs.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="phs.TF.1.4">
                  <label>4. </label>
                  <p>Combined data from <xref ref-type="bibr" rid="phs.REF.johnston.2005.609">Johnston et al [2005]</xref>, <xref ref-type="bibr" rid="phs.REF.johnston.2010.1142">Johnston et al [2010]</xref>, and <xref ref-type="bibr" rid="phs.REF.d_murger.2015.92">D&#x000e9;murger et al [2015]</xref></p>
                </fn>
                <fn id="phs.TF.1.5">
                  <label>5. </label>
                  <p>In eight (40%) of 20 persons with sub-PHS a <italic toggle="yes">GLI3</italic> pathogenic variant was identified; the pathogenic variants were similar to those identified in individuals with PHS [<xref ref-type="bibr" rid="phs.REF.johnston.2010.1142">Johnston et al 2010</xref>].</p>
                </fn>
                <fn id="phs.TF.1.6">
                  <label>6. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
                <fn id="phs.TF.1.7">
                  <label>7. </label>
                  <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
                </fn>
                <fn id="phs.TF.1.8">
                  <label>8. </label>
                  <p>In 5% of individuals with clinical features of PHS, no pathogenic variant in <italic toggle="yes">GLI3</italic> was found, suggesting at least one additional gene locus [<xref ref-type="bibr" rid="phs.REF.d_murger.2015.92">D&#x000e9;murger et al 2015</xref>] or cryptic variants in <italic toggle="yes">GLI3</italic> (including deep intronic or mosaic pathogenic variants).</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="phs.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="phs.Clinical_Description">
          <title>Clinical Description</title>
          <p>Pallister-Hall syndrome (PHS) displays a wide range of severity. The literature frequently reflects the assumption that PHS is severe and <related-object link-type="booklink" source-id="gene" document-id="gcps" document-type="chapter">Greig cephalopolysyndactyly syndrome</related-object> is mild. This is clearly incorrect, as a minority of individuals with PHS show multiple severe anomalies and most individuals with PHS are mildly affected with polydactyly, asymptomatic bifid epiglottis, and hypothalamic hamartoma. Without careful clinical evaluation, these individuals may be incorrectly diagnosed with postaxial polydactyly type A (PAP-A).</p>
          <p><bold>Hypothalamic hamartoma.</bold> Hypothalamic hamartoma is a malformation, not a tumor. Hypothalamic hamartomas grow at the rate of &#x02013; or more slowly than &#x02013; the surrounding brain tissue. Hypothalamic hamartomas may be large (&#x02264;4 cm in greatest dimension); little correlation exists between the size of the hypothalamic hamartoma and presence or severity of symptoms. Individuals with hypothalamic hamartomas may have neurologic symptoms, although most are asymptomatic. Removal of the hypothalamic hamartoma is not indicated and often results in iatrogenic pituitary insufficiency or other complications.</p>
          <p><bold>Endocrine manifestations.</bold> The endocrine manifestations of a hypothalamic hamartoma range from isolated growth hormone deficiency or isolated precocious puberty to pan hypopituitarism, which can be life threatening. Cortisol deficiency can occur in individuals with nonfamilial PHS, but appears to be rare in those with familial PHS.</p>
          <p><bold>Neurologic findings.</bold> The best-described neurologic complication of hypothalamic hamartoma is gelastic epilepsy, a partial complex seizure manifest by clonic movements of the chest and diaphragm that simulate laughing. Other types of seizures may be caused by hypothalamic hamartoma. Seizures associated with hypothalamic hamartoma in individuals with PHS are generally milder and are responsive to treatment, in contrast to individuals with nonsyndromic hypothalamic hamartoma, who often have refractory seizures [<xref ref-type="bibr" rid="phs.REF.boudreau.2005.42">Boudreau et al 2005</xref>]. No individual with PHS has been shown to have visual field loss even with a hypothalamic hamartoma near the optic chiasm.</p>
          <p><bold>Polydactyly.</bold> Postaxial polydactyly may be more common than mesoaxial polydactyly in individuals with PHS. Postaxial polydactyly (PAP) type A is the presence of a well-formed digit on the ulnar or fibular aspect of the limb. PAP type B is the presence of a rudimentary digit or nubbin in the same location. Mesoaxial (i.e., insertional or central) polydactyly is the presence of six or more well-formed digits with a 'Y'-shaped metacarpal or metatarsal.</p>
          <p>Note: The nonspecificity of postaxial polydactyly and the high frequency of PAP type B in persons of central African descent require caution in its use as a diagnostic feature.</p>
          <p><bold>Epiglottic abnormalities.</bold> Bifid epiglottis is nearly always asymptomatic; however, the more severe clefts of the larynx reported in individuals with PHS can cause severe airway symptoms. Posterior laryngeal clefts can be fatal.</p>
          <p><bold>Psychiatric and neuropsychological findings.</bold> Some individuals with PHS have behavioral manifestations including a few with severe intellectual disability and behavioral disturbances [<xref ref-type="bibr" rid="phs.REF.ng.2004.296">Ng et al 2004</xref>]. A larger study of behavioral manifestations of this disorder was inconclusive, reflecting the difficulty of assessing mild behavioral phenotypes in rare disorders [<xref ref-type="bibr" rid="phs.REF.azzam.2005.87">Azzam et al 2005</xref>].</p>
          <p><bold>Genitourinary anomalies.</bold> Renal abnormalities include cystic malformations, renal hypoplasia, and ectopic ureteral implantation; genitourinary anomalies include hydrometrocolpos. The pathogenetic mechanism of the genitourinary anomalies has been delineated [<xref ref-type="bibr" rid="phs.REF.blake.2016.437">Blake et al 2016</xref>].</p>
          <p><bold>Other</bold> findings include imperforate anus, pulmonary segmentation anomalies including bilateral bilobed lungs, and non-polydactyly skeletal anomalies including short limbs.</p>
          <p><bold>The prognosis</bold> for an individual with PHS and no known family history of PHS is based on the malformations present in the individual. Literature surveys are not useful for the purpose of establishing the prognosis because reported persons tend to show bias of ascertainment to more severe involvement. Although PHS has been categorized as a member of the CAVE (<italic toggle="yes">c</italic>erebro<italic toggle="yes">a</italic>cro<italic toggle="yes">v</italic>isceral <italic toggle="yes">e</italic>arly lethality) group of disorders, few affected individuals have an early lethality phenotype. This early lethality is most likely attributable to pan hypopituitarism that is caused by pituitary or hypothalamic dysplasia or severe airway malformations such as laryngotracheal clefts. In addition, imperforate anus can cause serious complications if not recognized promptly. Thus, in the absence of life-threatening malformations, the prognosis should be assumed to be good for individuals with the nonfamilial occurrence of PHS. For individuals with a family history of affected family members, the prognosis is based on the degree of severity present in the family.</p>
          <sec id="phs.SubPHS">
            <title>Sub-PHS</title>
            <p>Sub-PHS is a descriptor applied to individuals who have features of PHS but do not meet the clinical criteria for diagnosis of PHS (see <xref ref-type="sec" rid="phs.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>). In one study, eight (40%) of 20 persons affected with sub-PHS had pathogenic variants in <italic toggle="yes">GLI3</italic> that were similar to the pathogenic variants in individuals with PHS [<xref ref-type="bibr" rid="phs.REF.johnston.2010.1142">Johnston et al 2010</xref>].</p>
          </sec>
        </sec>
        <sec id="phs.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>See <xref ref-type="fig" rid="phs.F1">Figure 1</xref>. The mutational spectra of GCPS and PHS are mostly distinct. GCPS is caused by pathogenic variants of all types, whereas PHS is only caused by truncating variants and one splice variant that generates a frameshift and a truncation. Within the frameshift variant category, a genotype-phenotype correlation has been demonstrated on two levels:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Class of variant.</bold> Pathogenic variants of all classes can cause Greig cephalopolysyndactyly syndrome (GCPS) whereas the majority of pathogenic variants that cause the allelic disorder PHS are frameshift variants. Haploinsufficiency for GLI3 causes GCPS, whereas truncating variants 3' of the zinc finger domain of <italic toggle="yes">GLI3</italic> generally cause PHS [<xref ref-type="bibr" rid="phs.REF.kang.1997.266">Kang et al 1997</xref>] (<xref ref-type="fig" rid="phs.F1">Figure 1A</xref>).</p>
            </list-item>
            <list-item>
              <p><bold>Variant position.</bold> Among all frameshift variants in <italic toggle="yes">GLI3</italic>, variants in the first third of the gene are only known to cause GCPS (<xref ref-type="fig" rid="phs.F1">Figure 1B</xref>). Frameshift variants in the middle third of the gene cause PHS and (uncommonly) GCPS. Frameshift variants in the final third of the gene cause GCPS. There is no apparent correlation of the variant position within each of the three regions and the severity of the corresponding phenotypes.</p>
            </list-item>
          </list>
        </sec>
        <sec id="phs.Penetrance">
          <title>Penetrance</title>
          <p>No instances of incomplete penetrance of PHS have been published.</p>
          <p><xref ref-type="bibr" rid="phs.REF.ng.2004.296">Ng et al [2004]</xref> reported one individual with apparent germline mosaicism without evident clinical features.</p>
        </sec>
        <sec id="phs.Nomenclature">
          <title>Nomenclature</title>
          <p>Other descriptors used include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Hypothalamic hamartoblastoma syndrome.</bold> This is incorrect as "blastoma" refers to tissues in which the neural elements of hamartomas are immature, and is also incorrect as it does not reflect the syndromic nature of the phenotype and may be confused with isolated hamartomas.</p>
            </list-item>
            <list-item>
              <p><bold>CAVE (<italic toggle="yes">c</italic>erebro<italic toggle="yes">a</italic>cro<italic toggle="yes">v</italic>isceral <italic toggle="yes">e</italic>arly lethality) complex.</bold> This designation is inappropriate as most individuals are mildly affected and do not manifest early lethality.</p>
            </list-item>
            <list-item>
              <p>
                <bold>Hall-Pallister syndrome</bold>
              </p>
            </list-item>
          </list>
          <p>Note: The abbreviation "HPS" is used for the <related-object link-type="booklink" source-id="gene" document-id="hps" document-type="chapter">Hermansky-Pudlak syndrome</related-object>.</p>
        </sec>
        <sec id="phs.Prevalence">
          <title>Prevalence</title>
          <p>PHS is rare. The prevalence is unknown. More than 100 affected persons are known to the author [Biesecker, personal observation] and a number of additional individuals have been reported (see, e.g., <xref ref-type="bibr" rid="phs.REF.d_murger.2015.92">D&#x000e9;murger et al [2015]</xref>). It is suspected that many individuals with postaxial polydactyly and asymptomatic hypothalamic hamartoma or bifid epiglottis may be misdiagnosed as having nonsyndromic PAP-A.</p>
          <p>PHS is pan ethnic.</p>
        </sec>
      </sec>
      <sec id="phs.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">GLI3.</italic></bold> Other phenotypes are associated with pathogenic variants in <italic toggle="yes">GLI3</italic>.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="gcps" document-type="chapter"><bold>Greig cephalopolysyndactyly syndrome</bold></related-object>
<bold>(GCPS)</bold> includes polydactyly that is commonly preaxial and may also be postaxial. The polydactyly is commonly associated with cutaneous syndactyly. Craniofacial features seen in GCPS include widely spaced eyes, broad forehead, and macrocephaly. Mesoaxial polydactyly and osseous syndactyly of the metacarpals are not part of GCPS.</p>
        <p>Most individuals with GCPS have pathogenic variants that cause haploinsufficiency of GLI3, although a few individuals with a single-nucleotide variant (SNV) have been described. However, it has not been demonstrated that these SNVs have stable mRNA or protein. If the stability of these molecules were reduced, the SNVs would result in functional haploinsufficiency. At least one individual with preaxial polydactyly type IV (PPDIV) has been reported to have a <italic toggle="yes">GLI3</italic> pathogenic variant [<xref ref-type="bibr" rid="phs.REF.radhakrishna.1999.645">Radhakrishna et al 1999</xref>] &#x02014; a finding consistent with clinical suspicion that PPDIV is a mild form of GCPS, in which the limb findings occur without the craniofacial features. However, the craniofacial findings are subtle and controversy exists as to the distinction between nonsyndromic PPDIV and mild GCPS [<xref ref-type="bibr" rid="phs.REF.biesecker.2006.465">Biesecker 2006</xref>].</p>
        <p><bold>Sub-GCPS</bold> is a descriptor applied to individuals who have features of GCPS, but do not meet clinical criteria for a diagnosis of GCPS. The clinical criteria for sub-GCPS include:</p>
        <list list-type="bullet">
          <list-item>
            <p>One of the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Preaxial polydactyly</p>
              </list-item>
              <list-item>
                <p>Broad thumbs or great toes</p>
              </list-item>
              <list-item>
                <p>Cutaneous syndactyly</p>
              </list-item>
              <list-item>
                <p>Macrocephaly</p>
              </list-item>
              <list-item>
                <p>Widely spaced eyes; OR</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Both of the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Postaxial polydactyly</p>
              </list-item>
              <list-item>
                <p>Hypoplasia of the corpus callosum</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>In one study, eight (29%) of 28 individuals who met these criteria had pathogenic variants in <italic toggle="yes">GLI3</italic> [<xref ref-type="bibr" rid="phs.REF.johnston.2010.1142">Johnston et al 2010</xref>].</p>
        <p><bold>Isolated postaxial polydactyly type A (PAP-A).</bold> Pathogenic variants in <italic toggle="yes">GLI3</italic> have been identified in individuals with PAP-A [<xref ref-type="bibr" rid="phs.REF.radhakrishna.1999.645">Radhakrishna et al 1999</xref>]. The PAP-A phenotype has also been shown to result from pathogenic variants in other genes.</p>
        <p><bold>Isolated preaxial polydactyly type IV (PPDIV)</bold> comprises preaxial polydactyly of the hands and/or feet in the absence of other malformations. The severity of the PPDIV is highly variable [<xref ref-type="bibr" rid="phs.REF.everman.2006">Everman 2006</xref>]. Because macrocephaly occurs in the general population and is common in GCPS, the presence of macrocephaly in a person with apparently isolated PPDIV is difficult to interpret.</p>
        <p><bold>Oral-facial-digital overlap syndrome</bold> is a descriptor used for individuals who have features that overlap with OFD and PHS. The criteria for this disorder:</p>
        <list list-type="bullet">
          <list-item>
            <p>Polydactyly; AND</p>
          </list-item>
          <list-item>
            <p>One of the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Oral frenula</p>
              </list-item>
              <list-item>
                <p>Oral hamartoma</p>
              </list-item>
              <list-item>
                <p>Cleft lip</p>
              </list-item>
              <list-item>
                <p>Cleft palate</p>
              </list-item>
              <list-item>
                <p>Cerebellar vermis hypoplasia</p>
              </list-item>
              <list-item>
                <p>Tibial hypoplasia</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>In one study, six (29%) of 21 individuals in this category had a pathogenic variant in <italic toggle="yes">GLI3</italic> [<xref ref-type="bibr" rid="phs.REF.johnston.2010.1142">Johnston et al 2010</xref>].</p>
      </sec>
      <sec id="phs.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
          <bold>Central polydactyly</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Oral-facial-digital syndrome type 6</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/277170">277170</ext-link>), caused by biallelic pathogenic variants in <italic toggle="yes">C5orf42</italic>, includes central polydactyly with hypoplasia of the cerebellar vermis. Renal agenesis and dysplasia have been described.</p>
          </list-item>
          <list-item>
            <p><bold>Holzgreve syndrome</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/236110">236110</ext-link>) includes central polydactyly, cleft palate, heart defect.</p>
          </list-item>
        </list>
        <p>
          <bold>Postaxial polydactyly</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="mkks" document-type="chapter"><bold>McKusick-Kaufman syndrome</bold></related-object>
<bold>(MKS)</bold> is characterized by the triad of hydrometrocolpos in females and genital malformations in males, postaxial polydactyly (PAP) or central polydactyly, and congenital heart disease (CHD). Pathogenic variants in <italic toggle="yes">MKKS</italic> have been found in individuals with MKS within the Amish population. Inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="bbs" document-type="chapter"><bold>Bardet-Biedl syndrome</bold></related-object>
<bold>(BBS)</bold> is characterized by rod-cone dystrophy, truncal obesity, postaxial polydactyly, cognitive impairment, male hypogonadotropic hypogonadism, complex female genitourinary malformations, and renal dysfunction, which is a major cause of morbidity and mortality. Hypothalamic hamartoma and bifid epiglottis are rare manifestations of BBS [<xref ref-type="bibr" rid="phs.REF.stevens.2005.447">Stevens &#x00026; Ledbetter 2005</xref>]. At least nineteen genes are associated with BBS: <italic toggle="yes">BBS1</italic>, <italic toggle="yes">BBS2</italic>, <italic toggle="yes">ARL6</italic>, <italic toggle="yes">BBS4</italic>, <italic toggle="yes">BBS5</italic>, <italic toggle="yes">MKKS</italic>, <italic toggle="yes">BBS7</italic>, <italic toggle="yes">TTC8</italic>, <italic toggle="yes">BBS9</italic>, <italic toggle="yes">BBS10</italic>, <italic toggle="yes">TRIM32</italic>, <italic toggle="yes">BBS12, MKS1</italic>, <italic toggle="yes">CEP290</italic>, <italic toggle="yes">WDPCP</italic>, <italic toggle="yes">SDCCAG8</italic>, <italic toggle="yes">LZTFL1</italic>, <italic toggle="yes">BBIP1</italic>, and <italic toggle="yes">IFT27</italic>. Inheritance is typically autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hos" document-type="chapter"><bold>Holt-Oram syndrome</bold></related-object>
<bold>(HOS)</bold> is characterized by: upper-extremity malformations involving radial, thenar, or carpal bones; a personal and/or family history of congenital heart malformation (most commonly ostium secundum atrial septal defect and ventricular septal defect, especially those occurring in the muscular trabeculated septum); and/or cardiac conduction disease. <italic toggle="yes">TBX5</italic> pathogenic variants are found in more than 70% of individuals who meet strict diagnostic criteria for HOS. Inheritance is autosomal dominant.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="slo" document-type="chapter"><bold>Smith-Lemli-Opitz syndrome</bold></related-object>
<bold>(SLOS)</bold> is a congenital multiple anomaly syndrome caused by an abnormality in cholesterol metabolism resulting from deficiency of the enzyme 7-dehydrocholesterol reductase. It is characterized by prenatal and postnatal growth retardation, microcephaly, moderate-to-severe intellectual disability, and multiple major and minor malformations including postaxial polydactyly. <italic toggle="yes">DHCR7</italic> is the only gene known to be associated with SLOS. Inheritance is autosomal recessive.</p>
          </list-item>
        </list>
        <p><bold>Hypothalamic hamartoma.</bold> Nonsyndromic or isolated hypothalamic hamartomas may cause either endocrine disturbance (most commonly, growth hormone deficiency or precocious puberty) or a severe neurologic picture of refractory seizures, behavior problems, and cognitive decline. Gelastic epilepsy may be associated. Somatic <italic toggle="yes">GLI3</italic> pathogenic variants have been identified in nonsyndromic hypothalamic hamartomas [<xref ref-type="bibr" rid="phs.REF.wallace.2008.653">Wallace et al 2008</xref>].</p>
      </sec>
      <sec id="phs.Management">
        <title>Management</title>
        <sec id="phs.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Pallister-Hall syndrome (PHS), the following evaluations are recommended if they have not already been completed:</p>
          <list list-type="bullet">
            <list-item>
              <p>Assessment for cortisol deficiency. This must be performed urgently in individuals who have no family history of PHS and in individuals who have family members with PHS and cortisol deficiency. Of note, adrenal crisis can be lethal in infants who have not undergone proper evaluation and treatment for adrenal insufficiency.</p>
            </list-item>
            <list-item>
              <p>Consultation by an endocrinologist, including evaluation of growth hormone secretion, FSH and LH secretion, and serum concentration of thyroid hormone in early infancy after evaluation for and treatment of ACTH deficiency</p>
            </list-item>
            <list-item>
              <p>Cranial MRI to establish the location and extent of hamartoma</p>
            </list-item>
            <list-item>
              <p>Neurologic examination to exclude signs of intracranial hypertension, which is not typical of hypothalamic hamartomas</p>
            </list-item>
            <list-item>
              <p>Visualization of the epiglottis by laryngoscopy; urgent evaluation by an otolaryngologist for laryngotracheal cleft when signs or symptoms of aspiration are present; elective evaluation by an otolaryngologist in asymptomatic individuals for the purpose of establishing the diagnosis or establishing the extent of anomalies</p>
            </list-item>
            <list-item>
              <p>Limb radiographs to distinguish postaxial polydactyly from central polydactyly</p>
            </list-item>
            <list-item>
              <p>Evaluation by a hand surgeon to assess the timing and surgical approach to correct the polydactyly. Note that the surgical correction of mesoaxial polydactyly is typically more complex than for postaxial polydactyly and should be undertaken by an expert surgeon.</p>
            </list-item>
            <list-item>
              <p>Renal ultrasonography to evaluate for renal anomalies</p>
            </list-item>
            <list-item>
              <p>Surgical consultation for imperforate anus or anal stenosis if present</p>
            </list-item>
            <list-item>
              <p>Developmental assessment</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="phs.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Endocrine abnormalities are treated as in the general population, with treatment for cortisol deficiency being the most urgent.</p>
          <p>Anal atresia or stenosis should be treated in standard fashion.</p>
          <p>Management of epiglottic abnormalities depends on the type of abnormality and extent of respiratory compromise and is the same as in the general population. Bifid epiglottis is commonly asymptomatic and most do not require treatment, unless accompanied by clear evidence of obstruction or associated with other anomalies, such as tracheal stenosis.</p>
          <p>Seizures are treated symptomatically. Seizures associated with PHS are commonly responsive to antiepileptic drugs (AEDs), whereas seizures associated with nonsyndromic hypothalamic hamartomas are more commonly refractory to AEDs.</p>
          <p>Repair of polydactyly should be undertaken on an elective basis.</p>
          <p>If developmental delays are detected, intervention and/or special education are indicated.</p>
          <p>Occupational therapy for manual dexterity of the hands may be necessary as some individuals with mesoaxial polydactyly have digital malalignment.</p>
        </sec>
        <sec id="phs.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Only under the most unusual circumstances should a hypothalamic hamartoma be removed or even biopsied because the complications of surgery and the need for lifelong hormone supplements postoperatively generally outweigh the benefits.</p>
          <p>Use of stimulants for attention deficit disorder should be considered carefully in persons with a CNS lesion that predisposes to seizures (e.g., hypothalamic hamartoma).</p>
        </sec>
        <sec id="phs.Surveillance">
          <title>Surveillance</title>
          <p>During childhood:</p>
          <list list-type="bullet">
            <list-item>
              <p>Annual medical evaluations to assess growth and monitor for signs of precocious puberty</p>
            </list-item>
            <list-item>
              <p>Annual screening for developmental delay or learning disorders</p>
            </list-item>
          </list>
        </sec>
        <sec id="phs.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>As noted in <xref ref-type="sec" rid="phs.Prevention_of_Secondary_Complication">Prevention of Secondary Complications</xref>, some stimulants (commonly used for attention deficit and hyperactivity disorders) may exacerbate seizures.</p>
        </sec>
        <sec id="phs.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate relatives at risk in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p>
          <list list-type="bullet">
            <list-item>
              <p>If the pathogenic variant in the family is known, molecular genetic testing can be used to clarify the genetic status of at-risk relatives.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant in the family is not known, clinical examination for polydactyly, laryngoscopy for bifid epiglottis, or MRI for hypothalamic hamartoma can be used to clarify the genetic status of at-risk relatives.</p>
            </list-item>
            <list-item>
              <p>The first-degree relative of a proband is considered affected if hypothalamic hamartoma or central or postaxial polydactyly are present in the relative. (Postaxial polydactyly type B can be used as a diagnostic criterion for first-degree relatives only in persons who are not of central African descent.)</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="phs.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="phs.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Pregnancy management of a woman affected with PHS should be attuned to guidelines for the specific manifestations of the disorder. For example, the management of pregnant women with gelastic epilepsy who need to take anticonvulsants is challenging. As there are no guidelines specific to PHS, the author recommends following general guidelines for anticonvulsants in pregnancy [<xref ref-type="bibr" rid="phs.REF.borthen.2012.78">Borthen &#x00026; Gilhus 2012</xref>].</p>
          <p>In general, women with epilepsy or a seizure disorder from any cause are at greater risk for mortality during pregnancy than pregnant women without a seizure disorder; use of antiepileptic medication during pregnancy reduces this risk. However, exposure to antiepileptic medication may increase the risk for adverse fetal outcome (depending on the drug used, the dose, and the stage of pregnancy at which medication is taken). Nevertheless, the risk of an adverse outcome to the fetus from antiepileptic medication exposure is often less than that associated with exposure to an untreated maternal seizure disorder. Therefore, use of antiepileptic medication to treat a maternal seizure disorder during pregnancy is typically recommended. Discussion of the risks and benefits of using a given antiepileptic drug during pregnancy should ideally take place prior to conception. Transitioning to a lower-risk medication prior to pregnancy may be possible [<xref ref-type="bibr" rid="phs.REF.sarma.2016.467">Sarma et al 2016</xref>].</p>
          <p>The management of fertility and pregnancy (which is uncommon in individuals with hypopituitarism) in individuals with hypopituitarism caused by PHS is similarly challenging and again, it is recommended that general guidelines be followed [<xref ref-type="bibr" rid="phs.REF.k_bler.2009.89">K&#x000fc;bler et al 2009</xref>].</p>
          <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.mothertobaby.org/">MotherToBaby</ext-link> for further information on medication use during pregnancy.</p>
        </sec>
        <sec id="phs.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="phs.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="phs.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Pallister-Hall syndrome (PHS) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="phs.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Approximately 75% of individuals diagnosed with PHS have an affected parent.</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing is recommended for the parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant (i.e., a proband with no known family history of PHS).</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">GLI3</italic> pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, two possible explanations are a <italic toggle="yes">de novo</italic> pathogenic variant in the proband or germline mosaicism in a parent.</p>
              <list list-type="bullet">
                <list-item>
                  <p><bold><italic toggle="yes">De novo</italic> pathogenic variant.</bold> The proportion of probands who have a <italic toggle="yes">de novo GLI3</italic> pathogenic variant is about 25%. Individuals with a <italic toggle="yes">de novo</italic>
<italic toggle="yes">GLI3</italic> pathogenic variant are generally more severely affected than individuals with a family history of PHS [JJ Johnston, unpublished data].</p>
                </list-item>
                <list-item>
                  <p><bold>Germline mosaicism.</bold> The description of a single parent with germline mosaicism for a <italic toggle="yes">GLI3</italic> pathogenic variant [<xref ref-type="bibr" rid="phs.REF.ng.2004.296">Ng et al 2004</xref>] does not allow for estimation of the frequency of this event for genetic recurrence risk estimates, but it must be considered as a possibility.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Because there has only been a single occurrence of parental germline mosaicism (and no reports of non-penetrance) reported to date, the parents of a proband with no known family history of PHS should be examined for evidence of extra digits. If there is no evidence of extra digits, it is reasonable to conclude that the probability of the parent being non-penetrant or mosaic is very low.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of a proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low, but greater than that of the general population because of the possibility of germline mosaicism. One instance of parental mosaicism has been reported [<xref ref-type="bibr" rid="phs.REF.ng.2004.296">Ng et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p>The risks to sibs of individuals with isolated hypothalamic hamartomas caused by somatic <italic toggle="yes">GLI3</italic> pathogenic variants is unknown.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with PHS has a 50% chance of inheriting the <italic toggle="yes">GLI3</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Because intrafamilial variability appears to be low, affected offspring would be expected to have clinical findings similar to those of the parent.</p>
            </list-item>
            <list-item>
              <p>The risk to offspring of individuals with isolated hypothalamic hamartomas caused by somatic <italic toggle="yes">GLI3</italic> pathogenic variants is unknown.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected or has a <italic toggle="yes">GLI3</italic> pathogenic variant, his or her family members are at risk.</p>
        </sec>
        <sec id="phs.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="phs.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk family members for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <italic toggle="yes">de novo</italic> pathogenic variant. As noted in <xref ref-type="sec" rid="phs.Risk_to_Family_Members">Risk to Family Members</xref>, <bold>Sibs of a proband</bold>, one instance of germline mosaicism and sib recurrence of PHS has been described. However, the actual risk for this phenomenon cannot be estimated from a single case, though it is clearly not common. Other possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="phs.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">GLI3</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for PHS are possible.</p>
          <p><bold>Ultrasound examination.</bold> In fetuses at 50% risk, prenatal ultrasound examination may detect polydactyly. However, a normal ultrasound examination does not eliminate the possibility of PHS in the fetus.</p>
        </sec>
      </sec>
      <sec id="phs.Resources">
        <title>Resources</title>
      </sec>
      <sec id="phs.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">GLI3</italic> extends over approximately 276 kb and includes 15 exons. The mRNA is approximately 8 kb, the reference cDNA is 8,209 bp (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=119393898">NM_000168.3</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&#x00026;id=119393899">NP_000159.3</ext-link>), and the open reading frame is 4,740 bp. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="phs" object-id="phs.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign variants</bold>. A number of putative benign variants exist in <italic toggle="yes">GLI3</italic>; see <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="phs-table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> (pdf). Most of the variants have been seen in multiple unrelated persons and are not believed to be associated with any phenotypic effects, although they have not been rigorously analyzed for subtle effects. They are included in <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="phs-table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> if they lie within an exon or if they are in an intron within 25 bp of an exon. Readers should refer to the<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/snp/"> dbSNP</ext-link> reference number and information in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">ClinVar</ext-link>, <related-object source-id="gene" document-id="phs" object-id="phs.molgen.TA">Table A</related-object> (<bold>Locus Specific</bold> and <bold>HGMD</bold>), and the primary literature for confirmation and for additional data.</p>
        <p><bold>Pathogenic variants.</bold> Selected pathogenic variants reported in individuals with PHS are in <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="phs-table3.pdf" content-type="local-data">Table 3</inline-supplementary-material> (pdf). Multiple <italic toggle="yes">de novo</italic> pathogenic variants have been identified by <xref ref-type="bibr" rid="phs.REF.johnston.2005.609">Johnston et al [2005]</xref>, <xref ref-type="bibr" rid="phs.REF.johnston.2010.1142">Johnston et al [2010]</xref>, and <xref ref-type="bibr" rid="phs.REF.d_murger.2015.92">D&#x000e9;murger et al [2015]</xref>.</p>
        <p><bold>Normal gene product.</bold> The gene encodes a protein of 1,580 amino acids.</p>
        <p>Note: As the result of a cDNA sequencing error, older citations described a longer open reading frame that predicted a protein of 1,596 amino acids; the error has been corrected in the GenBank entry <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=119393898">NM_000168.3</ext-link>.</p>
        <p><bold>Abnormal gene product.</bold> It has been shown that truncated forms of the GLI3 protein repress transcription [<xref ref-type="bibr" rid="phs.REF.blake.2016.437">Blake et al 2016</xref>].</p>
      </sec>
      <sec id="phs.References">
        <title>References</title>
        <sec id="phs.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="phs.Literature_Cited.reflist0">
            <ref id="phs.REF.azzam.2005.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Azzam</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerner</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiggs</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenstein</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Psychiatric and neuropsychological characterization of Pallister-Hall syndrome.</article-title>
                <source>Clin Genet</source>
                <volume>67</volume>
                <fpage>87</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">15617553</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.biesecker.2006.465">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>What you can learn from one gene: GLI3.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>465</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16740916</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.blake.2016.437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blake</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cain</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenblum</surname>
                    <given-names>ND</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Urogenital development in Pallister-Hall syndrome is disrupted in a cell-lineage-specific manner by constitutive expression of GLI3 repressor.</article-title>
                <source>Hum Mol Genet.</source>
                <volume>25</volume>
                <fpage>437</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">26604140</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.borthen.2012.78">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Borthen</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilhus</surname>
                    <given-names>NE</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Pregnancy complications in patients with epilepsy.</article-title>
                <source>Curr Opin Obstet Gynecol.</source>
                <volume>24</volume>
                <fpage>78</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">22327733</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.boudreau.2005.42">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boudreau</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liow</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frattali</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiggs</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feuillan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patsalides</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patronas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theodore</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Hypothalamic hamartomas and seizures: distinct natural history of isolated and Pallister-Hall syndrome cases.</article-title>
                <source>Epilepsia</source>
                <volume>46</volume>
                <fpage>42</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15660767</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.d_murger.2015.92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x000e9;murger</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichkou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mougou-Zerelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Merrer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudefroye</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delezoide</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qu&#x000e9;lin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manouvrier</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baujat</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fradin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Megarban&#x000e9;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faivre</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nampoothiri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roume</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isidor</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delrue</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercier</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philip</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holder</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krause</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laffargue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinico</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amram</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andr&#x000e9;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liquier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amiel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giuliano</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boute</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dieux-Coeslier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Afenjar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lackmy-Port-Lis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vincent-Delorme</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chauvet</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cormier-Daire</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devisme</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genevi&#x000e8;ve</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viot</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raoul</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romana</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzales</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Encha-Razavi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Odent</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vekemans</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Attie-Bitach</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>New insights into genotype-phenotype correlation for GLI3 mutations.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2015</year>
                <volume>23</volume>
                <fpage>92</fpage>
                <lpage>102</lpage>
                <pub-id pub-id-type="pmid">24736735</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.everman.2006">
              <mixed-citation publication-type="book">Everman D. The polydactylies. In: Stevenson RE, Hall JG, eds. <italic toggle="yes">Human Malformations and Related Anomalies.</italic> 2 ed. Oxford, UK: Oxford University Press; 2006:937-53.</mixed-citation>
            </ref>
            <ref id="phs.REF.johnston.2005.609">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivos-Glander</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Killoran</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abbott</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aughton</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aylsworth</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bamshad</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Booth</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curry</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dinulos</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flannery</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grange</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guttmacher</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannibal</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henn</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennekam</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoyme</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leppig</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macleod</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manchester</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcelis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzanti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendelsohn</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moeschler</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moghaddam</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newbury-Ecob</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagon</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadler</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoler</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tilstra</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh Vockley</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zackai</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zadeh</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brueton</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations.</article-title>
                <source>Am J Hum Genet</source>
                <volume>76</volume>
                <fpage>609</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">15739154</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.johnston.2010.1142">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sapp</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amor</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aftimos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aleck</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bocian</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodurtha</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curry</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Day</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnai</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Field</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiwara</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabbett</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedera</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennekam</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hersh</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kayserili</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kidd</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimonis</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maisenbacher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGaughran</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raygada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robin</surname>
                    <given-names>NH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rope</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>KN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shealy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soller</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sommer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalker</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steiner</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephan</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tilstra</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomkins</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trapane</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Allen</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasudevan</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zunich</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Molecular analysis expands the spectrum of phenotypes associated with GLI3 mutations.</article-title>
                <source>Hum Mutat.</source>
                <volume>31</volume>
                <fpage>1142</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">20672375</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.kang.1997.266">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>JM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Olney</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <article-title>GLI3 frameshift mutations cause autosomal dominant Pallister-Hall syndrome.</article-title>
                <source>Nat Genet.</source>
                <year>1997</year>
                <volume>15</volume>
                <fpage>266</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9054938</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.k_bler.2009.89">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>K&#x000fc;bler</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klingm&#x000fc;ller</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gembruch</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merz</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>High-risk pregnancy management in women with hypopituitarism.</article-title>
                <source>J Perinatol.</source>
                <volume>29</volume>
                <fpage>89</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">19177043</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.ng.2004.296">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ng</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boudreau</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiggs</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theodore</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Gonadal mosaicism in severe Pallister-Hall syndrome.</article-title>
                <source>Am J Med Genet</source>
                <volume>124A</volume>
                <fpage>296</fpage>
                <lpage>302</lpage>
                <pub-id pub-id-type="pmid">14708104</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.radhakrishna.1999.645">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Radhakrishna</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bornholdt</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>UC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bottani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chandal</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blouin</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solanki</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grzeschik</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonarakis</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type- A/B; No phenotype prediction from the position of GLI3 mutations.</article-title>
                <source>Am J Hum Genet</source>
                <volume>65</volume>
                <fpage>645</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">10441570</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.sarma.2016.467">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sarma</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khandker</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurczewski</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brophy</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <article-title>Medical management of epileptic seizures: challenges and solutions.</article-title>
                <source>Neuropsychiatr Dis Treat.</source>
                <year>2016</year>
                <volume>12</volume>
                <fpage>467</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">26966367</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.stevens.2005.447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stevens</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledbetter</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Significance of bifid epiglottis.</article-title>
                <source>Am J Med Genet A</source>
                <volume>134</volume>
                <fpage>447</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15782417</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.wallace.2008.653">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freeman</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shouri</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Izzillo</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenfeld</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulley</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harvey</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Somatic mutations in GLI3 can cause hypothalamic hamartoma and gelastic seizures.</article-title>
                <source>Neurology.</source>
                <volume>70</volume>
                <fpage>653</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18057317</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="phs.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="phs.Suggested_Reading.reflist0">
            <ref id="phs.REF.biesecker.1996.76">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abbott</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clericuzio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feuillan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>JM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olney</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lefton</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verloes</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Report from the workshop on Pallister-Hall syndrome and related phenotypes.</article-title>
                <source>Am J Med Genet</source>
                <volume>65</volume>
                <fpage>76</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">8914745</pub-id>
              </element-citation>
            </ref>
            <ref id="phs.REF.johnston.2007">
              <mixed-citation publication-type="web">Johnston JJ, Biesecker LG. Pallister Hall syndrome (PHS). <italic toggle="yes">Atlas of Genetics and Cytogenetics Oncology and Haematology.</italic> Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://atlasgeneticsoncology.org/Kprones/PallisterHallID10126.html">online</ext-link>. 2007. Accessed 5-10-17.</mixed-citation>
            </ref>
            <ref id="phs.REF.vortkamp.1991.539">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vortkamp</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gessler</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grzeschik</surname>
                    <given-names>KH</given-names>
                  </name>
                </person-group>
                <year>1991</year>
                <article-title>GLI3 zinc-finger gene interrupted by translocations in Greig syndrome families.</article-title>
                <source>Nature</source>
                <volume>352</volume>
                <fpage>539</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">1650914</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="phs.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="phs.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.genome.gov/page.cfm?pageID=10000356">Author's Web page</ext-link>
          </p>
          <p>The author is a board-certified clinical geneticist and pediatrician. He performs clinical and molecular research on PHS and related disorders at the NIH.</p>
        </sec>
        <sec id="phs.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>18 May 2017 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>18 December 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>13 September 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 June 2010 (cd) Revision: deletion/duplication analysis no longer available clinically</p>
            </list-item>
            <list-item>
              <p>3 February 2009 (cd) Revision: deletion/duplication analysis available clinically</p>
            </list-item>
            <list-item>
              <p>18 March 2008 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>2 June 2006 (cd) Revision: prenatal diagnosis clinically available</p>
            </list-item>
            <list-item>
              <p>6 June 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>1 May 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>25 May 2000 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>20 January 2000 (lb) Original submission</p>
            </list-item>
          </list>
          <p>Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the <italic toggle="yes">GeneReview</italic> &#x02018;Pallister-Hall Syndrome&#x02019; is in the public domain in the United States of America.</p>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="phs.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>The mutational spectra of PHS and GCPS are mostly distinct.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="phs-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
